MRKMerck Sharp & Dohme LLCRunning, no new patients
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Renal Cell Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 272 (planned)
- Started
- Apr 10, 2024
- Main results expected
- Jan 8, 2028
- Fully finished
- Jun 8, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease-Free Survival (DFS)
Measured over: up to ~43 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06307431 · record last updated 2026-07-13 · checked 2026-11-09 15:47 UTC